Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

RA Capital Management

Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:

Top 5 stock holdings are ASND, PCVX, RYTM, TYRA, SION, and represent 47.28% of Ra Capital Management's stock portfolio.
Added to shares of these 10 stocks: Spyglass Pharma (+$208M), ZLAB (+$107M), SRPT (+$85M), DNTH (+$84M), NUVL (+$67M), WVE (+$64M), DMRA (+$62M), XNCR (+$59M), PCVX (+$44M), IPSC (+$40M).
Started 24 new stock positions in DMRA, MGNX, MPLT, ACRS, Aktis Oncology, ZLAB, IPSC, EQ, Helix Acquisition Corp Iii, STRO. RLMD, OKUR, KPTI, DRUG, SRPT, XNCR, RNA, ALXO, AVR, BIOA, Spyglass Pharma, MIRM, TVTX, CRVS.
Reduced shares in these 10 stocks: CDTX (-$743M), Avidity Biosciences Ord (-$623M), ACLX (-$83M), BLTE (-$69M), IVVD (-$42M), MDLN (-$14M), CTNM (-$12M), FDMT (-$5.6M), PGNY, Qiagen Nv.
Sold out of its positions in IVVD, ACLX, Avidity Biosciences Ord, BLTE, CDTX, HCAT, MDLN, KIDS, PGNY, Qiagen Nv.
Ra Capital Management was a net seller of stock by $-329M.
Ra Capital Management has $9.4B in assets under management (AUM), dropping by -2.99%.
Central Index Key (CIK): 0001346824

Tip: Access up to 7 years of quarterly data

Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Ra Capital Management

Ra Capital Management holds 85 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Ascendis Pharma A/s - Sponsored Adr (ASND)	24.9	$2.4B		10M	228.73	View chart
Vaxcyte Common Stock (PCVX)	7.1	$667M	+6%	12M	58.11	View chart
Rhythm Pharmaceuticals Common Stock (RYTM)	6.1	$580M		6.7M	86.97	View chart
Tyra Biosciences Common Stock (TYRA)	5.0	$467M		12M	38.30	View chart
Sionna Therapeutics Common Stock (SION)	4.2	$397M		9.9M	40.09	View chart
Edgewise Therapeutics Common Stock (EWTX)	3.5	$329M		10M	31.50	View chart
Newamsterdam Pharma Co Nv Common Stock (NAMS)	3.2	$306M		9.6M	32.01	View chart
Nuvalent Inc-a Common Stock (NUVL)	2.8	$260M	+34%	2.5M	102.45	View chart
Dianthus Therapeutics Common Stock (DNTH)	2.3	$219M	+62%	2.6M	83.92	View chart
Mineralys Therapeutics Common Stock (MLYS)	2.2	$208M	+5%	7.7M	27.09	View chart
Spyglass Pharma Common Stock	2.2	$208M	NEW	8.0M	25.91	View chart
Wave Life Sciences Common Stock (WVE)	2.1	$196M	+48%	27M	7.25	View chart
Septerna Common Stock (SEPN)	1.8	$168M		7.0M	24.03	View chart
Disc Medicine Common Stock (IRON)	1.7	$157M	+23%	2.5M	63.94	View chart
Janux Therapeutics Common Stock (JANX)	1.6	$156M		11M	13.90	View chart
Biocryst Pharmaceuticals Common Stock (BCRX)	1.6	$151M		16M	9.52	View chart
Bicara Therapeutics Common Stock (BCAX)	1.5	$144M	+4%	7.3M	19.89	View chart
Praxis Precision Medicines I Common Stock (PRAX)	1.3	$120M		374k	322.19	View chart
Gh Research Common Stock (GHRS)	1.1	$108M		7.7M	14.06	View chart
Zai Lab Ltd- Common Stock (ZLAB)	1.1	$107M	NEW	5.7M	18.81	View chart
Taysha Gene Therapies Common Stock (TSHA)	1.1	$105M		24M	4.47	View chart
Vor Biopharma Common Stock (VOR)	1.0	$96M		5.4M	17.84	View chart
Geron Corp Common Stock (GERN)	1.0	$95M		64M	1.49	View chart
Ars Pharmaceuticals Common Stock (SPRY)	0.9	$87M		11M	8.03	View chart
Sarepta Therapeutics Common Stock (SRPT)	0.9	$85M	NEW	3.9M	21.76	View chart
Spyre Therapeutics Common Stock (SYRE)	0.9	$82M		1.6M	50.44	View chart
Evommune Common Stock (EVMN)	0.9	$80M		3.5M	22.99	View chart
Climb Bio Common Stock (CLYM)	0.8	$77M		11M	6.85	View chart
Solid Biosciences Common Stock (SLDB)	0.7	$67M	+60%	9.3M	7.20	View chart
Artiva Biotherapeutics Common Stock (ARTV)	0.7	$64M		9.9M	6.44	View chart
Damora Therapeutics Common Stock (DMRA)	0.7	$62M	NEW	2.4M	25.90	View chart
Xencor Common Stock (XNCR)	0.6	$59M	NEW	4.9M	12.06	View chart
Lb Pharmaceuticals Common Stock (LBRX)	0.6	$55M		2.2M	24.66	View chart
Jade Biosciences Common Stock (JBIO)	0.5	$52M		3.7M	14.05	View chart
Acumen Pharmaceuticals Common Stock (ABOS)	0.5	$50M	+40%	21M	2.36	View chart
4d Molecular Therapeutics In Common Stock (FDMT)	0.5	$47M	-10%	5.0M	9.31	View chart
Fulcrum Therapeutics Common Stock (FULC)	0.5	$46M		6.1M	7.67	View chart
Capricor Therapeutics Common Stock (CAPR)	0.5	$46M		1.5M	30.40	View chart
Century Therapeutics Common Stock (IPSC)	0.4	$40M	NEW	18M	2.26	View chart
Olema Pharmaceuticals Common Stock (OLMA)	0.4	$39M		2.6M	14.91	View chart
Lenz Therapeutics Common Stock (LENZ)	0.4	$38M		4.2M	9.15	View chart
Monopar Therapeutics Common Stock (MNPR)	0.4	$37M		667k	54.79	View chart
Pepgen Common Stock (PEPG)	0.4	$36M		20M	1.77	View chart
Design Therapeutics Common Stock (DSGN)	0.3	$32M	+103%	3.0M	10.64	View chart
Mirum Pharmaceuticals Common Stock (MIRM)	0.3	$29M	NEW	319k	92.38	View chart
Bioage Labs Common Stock (BIOA)	0.3	$29M	NEW	1.7M	17.49	View chart
Lexeo Therapeutics Common Stock (LXEO)	0.3	$29M		5.0M	5.74	View chart
Assembly Biosciences Common Stock (ASMB)	0.3	$28M		1.0M	27.75	View chart
Rezolute Common Stock (RZLT)	0.3	$28M		9.2M	3.05	View chart
Aktis Oncology Common Stock	0.3	$27M	NEW	1.5M	17.89	View chart
Alx Oncology Holdings Common Stock (ALXO)	0.3	$26M	NEW	13M	2.00	View chart
Aclaris Therapeutics Common Stock (ACRS)	0.3	$26M	NEW	6.8M	3.75	View chart
Ovid Therapeutics Common Stock (OVID)	0.3	$24M		11M	2.22	View chart
Nkarta Common Stock (NKTX)	0.2	$23M		11M	2.11	View chart
Travere Therapeutics Common Stock (TVTX)	0.2	$22M	NEW	747k	29.71	View chart
Grail Common Stock (GRAL)	0.2	$22M		428k	51.68	View chart
C4 Therapeutics Common Stock (CCCC)	0.2	$21M		8.0M	2.63	View chart
Relmada Therapeutics Common Stock (RLMD)	0.2	$21M	NEW	2.9M	6.96	View chart
Benitec Biopharma Common Stock (BNTC)	0.2	$20M		1.9M	10.65	View chart
Bright Minds Biosciences Common Stock (DRUG)	0.2	$19M	NEW	265k	72.97	View chart
Sutro Biopharma Common Stock (STRO)	0.2	$18M	NEW	715k	24.91	View chart
Contineum Therapeutics Inc-a Common Stock (CTNM)	0.2	$17M	-40%	1.3M	13.06	View chart
Sab Biotherapeutics Common Stock (SABS)	0.2	$17M		4.4M	3.83	View chart
Inspire Medical Systems Common Stock (INSP)	0.2	$17M	+129%	326k	51.58	View chart
Anteris Technologies Global Common Stock (AVR)	0.2	$17M	NEW	3.0M	5.55	View chart
Onkure Therapeutics Inc-a Common Stock (OKUR)	0.2	$17M	NEW	4.0M	4.14	View chart
Hinge Health Inc-a Common Stock (HNGE)	0.1	$14M	+355%	365k	38.56	View chart
Genedx Holdings Corp Common Stock (WGS)	0.1	$14M	+261%	210k	64.22	View chart
Waystar Holding Corp Common Stock (WAY)	0.1	$13M	+266%	529k	24.11	View chart
Helix Acquisition Corp-cl A Common Stock	0.1	$13M	NEW	1.3M	10.16	View chart
Palisade Bio Common Stock (PALI)	0.1	$13M		7.1M	1.75	View chart
Acrivon Therapeutics Common Stock (ACRV)	0.1	$12M		8.3M	1.39	View chart
Atrium Therapeutics Common Stock (RNA)	0.1	$12M	NEW	864k	13.37	View chart
Karyopharm Therapeutics Common Stock (KPTI)	0.1	$11M	NEW	1.9M	5.57	View chart
Avalo Therapeutics Common Stock (AVTX)	0.1	$9.9M		663k	14.93	View chart
Perceptive Capital Solutions Common Stock (PCSC)	0.1	$8.2M		750k	10.97	View chart
Adicet Bio Common Stock (ACET)	0.1	$8.1M	+24%	1.2M	6.81	View chart
Newamsterdam Pharma Co Nv-27 W Exp 99/99/999 (NAMSW)	0.1	$6.7M		333k	20.04	View chart
Corvus Pharmaceuticals Common Stock (CRVS)	0.1	$6.6M	NEW	450k	14.63	View chart
Rani Therapeutics Holdings-a Common Stock (RANI)	0.1	$6.2M		8.5M	0.73	View chart
Equillium Common Stock (EQ)	0.1	$6.2M	NEW	3.1M	2.00	View chart
Werewolf Therapeutics Common Stock (HOWL)	0.1	$5.6M		6.7M	0.83	View chart
Macrogenics Common Stock (MGNX)	0.1	$5.4M	NEW	1.9M	2.89	View chart
Maplight Therapeutics Common Stock (MPLT)	0.1	$5.0M	NEW	248k	20.33	View chart
Palatin Technologies Common Stock (PTN)	0.0	$1.2M		70k	17.42	View chart

Past Filings by Ra Capital Management

SEC 13F filings are viewable for Ra Capital Management going back to 2010

Ra Capital Management 2026 Q1 filed May 15, 2026
Ra Capital Management 2025 Q4 filed Feb. 17, 2026
Ra Capital Management 2025 Q3 filed Nov. 14, 2025
Ra Capital Management 2025 Q2 filed Aug. 14, 2025
Ra Capital Management 2025 Q1 filed May 15, 2025
Ra Capital Management 2024 Q4 filed Feb. 14, 2025
Ra Capital Management 2024 Q3 filed Nov. 14, 2024
Ra Capital Management 2024 Q2 filed Aug. 14, 2024
Ra Capital Management 2024 Q1 amended filed May 17, 2024
Ra Capital Management 2024 Q1 filed May 15, 2024
Ra Capital Management 2023 Q4 filed Feb. 14, 2024
Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
Ra Capital Management 2023 Q3 filed Nov. 14, 2023
Ra Capital Management 2023 Q2 filed Aug. 14, 2023
Ra Capital Management 2023 Q1 filed May 15, 2023
Ra Capital Management 2022 Q4 filed Feb. 14, 2023

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z